Insights

Strategic partnerships OncoNano has a growing collaboration footprint with major pharma players (notably a January 2026 partnership with Gilead) which signals openness to co-development and technology licensing. This presents a sales opportunity to explore complementary collaboration, co-development, or licensing deals for ON-BOARD technology with additional oncology leaders seeking targeted delivery platforms.

Clinical momentum The company is advancing a pipeline with preclinical and clinical-stage milestones and has recent activity at AACR and ASCO, indicating ongoing proof-of-concept and data generation. Sales teams can target oncology biomarkers or therapeutic payloads that benefit from pH-activated, tumor-targeted delivery to align with their ongoing discussions and future trials.

Platform leverage ON-BOARD encapsulation platform aims to improve pharmacokinetics and pharmacodynamics across payload types from small molecules to biologics. This broad applicability opens doors for partnering opportunities across diverse drug modalities and allows pitching to multiple business units within potential partners who seek enhanced stability and tumor selectivity.

Funding and scale With substantial funding and revenue in the tens of millions range and a sizable fundraising runway, OncoNano is positioned to invest in collaboration programs, joint development, or sponsored research. This supports long-term BD engagements with potential customers seeking payload optimization through their platform without up-front risk.

Leadership and focus Recent executive appointments and leadership emphasis on R&D signal a strategic push toward expanding the pipeline and clinical execution. BD teams can engage around structured programs with clear milestones, targeting senior decision-makers responsible for external collaborations and strategic partnerships in oncology.

Similar companies to OncoNano Medicine, Inc.

OncoNano Medicine, Inc. Tech Stack

OncoNano Medicine, Inc. uses 8 technology products and services including Squarespace, WordPress, Shopify, and more. Explore OncoNano Medicine, Inc.'s tech stack below.

Media & News

OncoNano Medicine, Inc.'s Email Address Formats

OncoNano Medicine, Inc. uses at least 6 email formats:
OncoNano Medicine, Inc. Email FormatsExamplePercentage
FLast@onconanomed.comJDoe@onconanomed.com
82%
Last@onconanomed.comDoe@onconanomed.com
9%
First@onconanomed.comJohn@onconanomed.com
6%
First_Last@onconanomed.comJohn_Doe@onconanomed.com
3%
FLast@onconano.comJDoe@onconano.com
67%
Last@onconano.comDoe@onconano.com
33%

Frequently Asked Questions

What is OncoNano Medicine, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact OncoNano Medicine, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is OncoNano Medicine, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
OncoNano Medicine, Inc.'s official website is onconano.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does OncoNano Medicine, Inc. generate?

Minus sign iconPlus sign icon
As of October 2026, OncoNano Medicine, Inc.'s annual revenue is estimated to be $10M - $25M.

What is OncoNano Medicine, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
OncoNano Medicine, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does OncoNano Medicine, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2026, OncoNano Medicine, Inc. has approximately 22 employees across 1 continents, including North America. Key team members include Vice President Technical Operations: H., Founder: B. S. and Sr. Director Of Quality Assurance: R. M. Explore OncoNano Medicine, Inc.'s employee directory with LeadIQ.

What industry does OncoNano Medicine, Inc. belong to?

Minus sign iconPlus sign icon
OncoNano Medicine, Inc. operates in the Biotechnology Research industry.

What technology does OncoNano Medicine, Inc. use?

Minus sign iconPlus sign icon
OncoNano Medicine, Inc.'s tech stack includes Squarespace, WordPress, Shopify, Squarespace Commerce, Microsoft 365, Google Cloud, WP Engine and Vimeo.

What is OncoNano Medicine, Inc.'s email format?

Minus sign iconPlus sign icon
OncoNano Medicine, Inc.'s email format typically follows the pattern of FLast@onconanomed.com. Find more OncoNano Medicine, Inc. email formats with LeadIQ.

How much funding has OncoNano Medicine, Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2026, OncoNano Medicine, Inc. has raised $188M in funding. The last funding round occurred on Oct 25, 2021 for $18M.
OncoNano Medicine, Inc. logo

OncoNano Medicine, Inc.

Biotechnology ResearchTexas, United States11-50 Employees

OncoNano Medicine, Inc. is a small biotechnology company focused on oncology research, headquartered in Dallas, Texas. It develops targeted cancer therapies by encapsulating therapeutic payloads in its ON-BOARD polymeric micelle platform, leveraging the acidic tumor microenvironment to promote drug localization at tumor sites. By improving pharmacokinetic and pharmacodynamic properties of payloads—ranging from small molecules to larger biologics—these micelles support localized tumor targeting. The company serves oncology researchers and pharmaceutical developers seeking more precise cancer therapies with improved tumor targeting. It operates as a clinical-stage biotechnology company advancing precision cancer therapies. In January 2026, OncoNano announced a research collaboration with Gilead Sciences to evaluate its ON-BOARD encapsulation technology with a Gilead drug candidate.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $188M

    OncoNano Medicine, Inc. has raised a total of $188M of funding over 7 rounds. Their latest funding round was raised on Oct 25, 2021 in the amount of $18M as a Series B.

  • $10M - $25M

    OncoNano Medicine, Inc.'s revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.